title: The effect of adjunctive mitomycin C in Molteno implant surgery.
abstract: OBJECTIVE
  The purpose of the study is to assess the effect of adjunctive intraoperative mitomycin C (MMC) in Molteno drainage device implantation for patients with recalcitrant glaucomas.
  
  
  METHODS
  Forty-nine eyes of 49 patients who underwent one-stage, single-plate Molteno device implantation with adjunctive intraoperative MMC (0.5 mg/ml) for 3 to 5 minutes (MMC group) were compared to a historic control group of 51 eyes of 51 patients (control group) who received one-stage, single-plate Molteno device implantation without MMC. Success (survival) was defined as an intraocular pressure (IOP) between 6 and 21 mmHg, inclusive, with (qualified success) or without (complete success) glaucoma medications and with no additional glaucoma surgery, phthisis, implant removal, or loss of light perception.
  
  
  RESULTS
  Preoperative conditions were similar between the two groups. There was no significant difference in surgical survival rate between the two groups (P = 0.13, log-rank test). There also were no significant differences in the postoperative IOP levels and numbers of antiglaucoma medications between the two groups at all times (P > 0.05). Visual acuity was improved or remained within one line of preoperative visual acuity in 76.1% of the MMC group and 78.7% of the control group at 1 year after surgery (P = 0.76, chi-square test). Complications and reoperation for complications were similar in both groups (P > 0.05, chi-square test) except for the incidence of early postoperative hypotony and the total number of eyes with complications not requiring reoperation, which were more common in the MMC group (P = 0.027, 0.005, respectively, chi-square test). The most common complications included hypotony with or without a flat anterior chamber or choroidal detachment, followed by hyphema and tube plugging.
  
  
  CONCLUSIONS
  Molteno device implantation with adjunctive intraoperative MMC in patients with complicated glaucoma may not offer a better chance of surgical success compared with Molteno implantation without MMC.
authors.affiliation: Kresge Eye Institute, Wayne State University, Detroit, Michigan 48201-1423, USA.
authors.forename: D
authors.initials: D
authors.lastname: Lee
authors.forename: D H
authors.initials: DH
authors.lastname: Shin
authors.forename: C M
authors.initials: CM
authors.lastname: Birt
authors.forename: C
authors.initials: C
authors.lastname: Kim
authors.forename: T H
authors.initials: TH
authors.lastname: Kupin
authors.forename: M M
authors.initials: MM
authors.lastname: Olivier
authors.forename: A K
authors.initials: AK
authors.lastname: Khatana
authors.forename: S Y
authors.initials: SY
authors.lastname: Reed
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D005260:Female; D005901:Glaucoma / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure; D007430:Intraoperative Care; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D018465:Molteno Implants; D011183:Postoperative Complications; D012086:Reoperation; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D016685:Mitomycin